Captozyme Inc. was ranked 34 on the list with a CAGR of 48.54%. The company was recognized during a ceremony on Feb. 22.
A recombinant version of oxalate decarboxylase, called A0, which is being developed by Captozyme, Inc could give hope to patients with oxalosis and hyperoxaluria, according to a study presented at the World Congress of Endourology (WCE) in Paris, France. This is great news for organizations such as the The Oxalosis and Hyperoxaluria Foundation, working to help these patients.
After working with the Burdock Group to recently obtain a successful self-contained GRAS (Generally Recognized As Safe) determination for its oxalate-reducing enzyme, biotechnology company Captozyme licensed the rights for commercialization to Entring LLC, which will make it available for purchase this fall as a food ingredient. Consumers seeking a low-oxalate diet can add the virtually tasteless, odorless powder to a variety of oxalate-packed foods and beverages to help reduce the presence of the anti-nutrient.
Helena Cowley, CEO of Captozyme, which was named a GrowFL Company To Watch in 2017, was the company's first employee. She never set out to be an entrepreneur, but says the process of growing the company has certainly turned her into one.
The biotechnology company Captozyme is spearheading an innovative approach to nutrition to prevent the formation of painful kidney stones and other complications arising from the absorption of calcium oxalate from food. The company’s research efforts are led by Dr Qing-Shan Li, co-founder and CSO of the company.